Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAngele KotomaleMAMonica Ahlquist

Discussion

Loading...

Member takes

Overview

Observational analysis shows high response rates in relapsed/refractory multiple myeloma patients treated with talquetamab, indicating effectiveness in community settings.

Key Points

  • Overall, the real-world overall response rate reached 81.0% at 10.8 months of duration with talquetamab therapy for patients with relapsed/refractory disease.
  • Patients achieved high rates of progression-free survival, with 82.5% remaining progression-free at the 6-month mark after treatment initiation.
  • A retrospective observational study leveraged data from community settings, highlighting practical treatment patterns and patient demographics in multi-site environments.
  • Caution is warranted in interpretation due to the short follow-up period, indicating further investigation is required for long-term outcomes.

Cite This Study

Kotomale et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7ffhttps://doi.org/10.1182/blood-2025-2818
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  2. 2Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  3. 3Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials2025 · 1 citations
  4. 4Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  5. 5Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-12025 · 15 citations